Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.

HPV vaccination schedules have changed as evidence has supported reduced dosing and extended intervals. Women living with HIV (WLWH) represent an important population with no data on alternative dosing. Girls and WLWH received quadrivalent HPV (qHPV) vaccine in a pan-Canadian study of immunogenicity and efficacy. Serology was performed at months 0/2/7/12/18/24. Medical and sexual history was collected throughout. Linear regression was used to determine if spacing of doses was associated with peak antibody titer. Multivariable analyses demonstrated significant relationships between peak antibody titer and time to blood draw post last vaccine dose, naivety to the relevant HPV type, and HIV viral load for all qHPV types. There was a significant relationship between peak HPV16/18 antibody titer and age. Taking age, time to serology, CD4 cell count, CD4 nadir, HIV viral load, and HPV naivety into account, spacing of the three qHPV vaccine doses did not significantly impact peak antibody titers.

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Disclosure of Interests Ms. McClymont has no conflicts. Dr. Ogilvie is a co-investigator on an investigator-led trial funded by Hologic Inc and Roche. Dr. Albert has no conflicts. Dr. Johnston has no conflicts. Dr. Raboud is a co-investigator on three projects outside the submitted work, with in-kind contributions or financial support from Merck and Gilead Sciences. Dr. Walmsley has received grants, personal fees and non-financial support from Merck Canada Inc., ViiV Healthcare, Gilead, AbbVie, Janssen and Bristol Meyers Squibb for participation on advisory boards, presentations, meetings, studies, workshops and symposia for each, outside the submitted work. Ms. Lipsky has no conflicts. Dr. Loutfy has received grant and honoraria funding from Merck Canada Inc., ViiV Healthcare, and Gilead, unrelated to the submitted work. Dr. Trottier has received grants from ViiV Healthcare, Gilead, GlaxoSmithKline, and Merck, outside the submitted work. Dr. Smaill received grant and honoraria funding from Merck Canada Inc., ViiV Healthcare, and Gilead, unrelated to the submitted work. Dr. Yudin has no conflicts. Dr. Klein has received funding for investigator-initiated research from ViiV and Merck, unrelated to this work, and honoraria for participation in advisory boards from Merck, ViiV, and BMS. Dr. Harris has received grants, paid to the institution, from the Canadian Institutes of Health Research (CIHR) and honoraria for consultancy and/or speaking engagements from Gilead Sciences Canada Inc., Merck Canada Inc., and ViiV Healthcare, outside the submitted work. Dr. Wobeser has received grants, paid to the institution, from CIHR and Merck Canada Inc., as well as honoraria for consultancy and/or speaking engagements from ViiV Healthcare, Gilead, AbbVie, and Janssen outside of the submitted work. Dr. Bitnun has no conflicts. Dr. Kakkar has no conflicts. Dr. Samson has no conflicts. Dr. Brophy has received honoraria for consultancy work from Merck Canada Inc., outside the submitted work. Dr. Karatzios has no conflicts. Dr. Money has received grants from GSK and Merck Canada Inc. for conducting sponsored vaccine trials. She also reports grants from Novartis and Sanofi for conducting sponsored vaccine trials in an unrelated area. She has received personal fees for symposium participation from Merck Canada Inc., outside the submitted work.